Lin Shen, MD
Peking University Cancer Hospital, Beijing, Beijing 100142, China · Peking University Cancer Hospital & Institute · Department of Medical Oncology, Beijing
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lin Shen, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:27 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07700979 · Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaAkeso · recruiting · Gastric / Gastroesophageal Junction Adenocarcinoma · principal investigator
- Early Ph1NCT07673419 · A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung CancerBeijing Geekgene Technology Co., LTD · not yet recruiting · Advanced Lung Cancer · principal investigator
- N/ANCT07547787 · A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)Akeso · recruiting · Locally Advanced Unresectable or Metastatic Gastric Cancer · principal investigator
- Ph1/Ph2NCT07259590 · A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationGenfleet Therapeutics (Shanghai) Inc. · recruiting · Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer) · principal investigator
- Ph1NCT06541639 · EVM16 Injection as a Single and Combination With Tislelizumab in Solid TumorsPeking University · recruiting · Advanced or Recurrent Solid Tumors · principal investigator
- Ph3NCT06341335 · A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaAkeso · recruiting · Gastric and Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph2NCT06222944 · Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJAPeking University · unknown · Gastric Cancer, Adenocarcinoma of Esophagogastric Junction · principal investigator
- Ph3NCT06086457 · PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · recruiting · Esophageal Neoplasms · principal investigator
- Ph1/Ph2NCT05964543 · The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal TumorsQureBio Ltd. · unknown · Gastroesophageal Junction (GEJ) Adenocarcinoma · principal investigator
- Ph1/Ph2NCT05830097 · A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid TumorsCoherent Biopharma (Hefei) Co., Ltd. · unknown · Cancer, Breast, Cancer, Lung, Cancer of Pancreas · principal investigator
- Ph1NCT05751356 · TR128 in Patients With Advanced Solid TumorsTarapeutics Science Inc. · unknown · Advanced Solid Tumor · principal investigator
- N/ANCT05697107 · Ripretinib in Chinese Patients With Advanced GIST: a Real World StudyPeking University · unknown · Gastrointestinal Stromal Tumors · principal investigator
- N/ANCT05649163 · Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard TherapyShen Lin · unknown · HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph1NCT05393986 · Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid TumorsPeking University · unknown · Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma · principal investigator
- N/ANCT05227378 · Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric CancerShen Lin · unknown · Gastric Cancer · principal investigator
- Ph1/Ph2NCT05154201 · Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.Orinove, Inc. · completed · Effect of Drug · principal investigator
- Ph2NCT05030246 · Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerPeking University · unknown · Refractory Metastatic Digestive System Carcinoma, Primary Peritoneal Cancer · principal investigator
- Ph3NCT05008783 · A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ AdenocarcinomaAkeso · completed · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph1/Ph2NCT04982276 · A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaAkeso · recruiting · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph2NCT04923932 · Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsHutchison Medipharma Limited · completed · Gastric Cancer, Esophagogastric Junction Disorder · principal investigator
- Ph2NCT04891198 · ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors3D Medicines (Sichuan) Co., Ltd. · recruiting · Solid Tumor · principal investigator
- Ph2NCT04723030 · The Transformation of Locally Advanced Pancreatic Cancer.Peking University · unknown · Locally Advanced Pancreatic Cancer · principal investigator
- N/ANCT04584008 · Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsPeking University · unknown · Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma · principal investigator
- Ph1/Ph2NCT04254939 · A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCStone Pharmaceuticals · completed · Gastrointestinal Stromal Tumors · principal investigator
- Ph1NCT04130763 · Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1Peking University · completed · Gastrointestinal System Cancer · principal investigator
- Ph1NCT04040699 · KN026 Combined With KN046 in Subjects With HER2 Positive Solid TumorPeking University · completed · HER2 Positive Solid Tumor · principal investigator
- Ph1NCT03879057 · Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid TumorsPeking University · unknown · Solid Tumor · principal investigator
- Ph1NCT03710265 · SHR-1701 in Metastatic or Locally Advanced Solid TumorsJiangsu HengRui Medicine Co., Ltd. · unknown · Solid Tumor · principal investigator
- Ph2NCT03667170 · KN035 for dMMR/MSI-H Advanced Solid Tumors3D Medicines (Sichuan) Co., Ltd. · active not recruiting · Solid Tumor · principal investigator
- Ph2NCT03472365 · A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerJiangsu HengRui Medicine Co., Ltd. · completed · Gastric Cancer, GastroEsophageal Cancer · principal investigator
- Ph1NCT03312842 · A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid TumorsCStone Pharmaceuticals · completed · Advanced Cancer · principal investigator
- Ph1NCT03167853 · Study of JS001 in Patients With Advanced Neuroendocrine TumorsPeking University · completed · Neuroendocrine Tumors · principal investigator
- Ph2NCT03126708 · Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell CarcinomaPeking University · unknown · Esophageal Cancer, Squamous Cell, Cetuximab Effect, Chemotherapy Effect · principal investigator
- Ph2NCT02016274 · Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell CancerShen Lin · unknown · Esophageal Squamous Cell Cancer · principal investigator
- Ph2NCT02016287 · Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell CancerShen Lin · unknown · Esophageal Squamous Cell Cancer, Elderly Patients · principal investigator
- Ph1/Ph2NCT01993784 · Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.Peking University · unknown · Esophageal Squamous Cell Cancer · principal investigator
- N/ANCT01847794 · HER2 Positive CTC in Advanced Gastric CancerPeking University · unknown · HER2 Positive Advanced Gastric Cancer · principal investigator
- N/ANCT01848015 · Circulating Tumor Cells (CTCs) in Advanced Gastric CancerPeking University · unknown · Gastric Cancer · principal investigator
- N/ANCT01549067 · The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation SurveyChinese Medical Doctor Association · unknown · Advanced Malignant Neoplasm, Colorectal Cancer · principal investigator
- Ph3NCT01015339 · Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionPeking University · unknown · Advanced Gastric Cancer · principal investigator
- Ph2NCT00842491 · Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric CancerPeking University · completed · Advanced Gastric Cancer · principal investigator
- Ph3NCT00630045 · Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver MetastasisPeking University People's Hospital · unknown · Colorectal Cancer, Resectable Liver Metastasis · principal investigator
- Ph2NCT00477711 · A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric CancerPeking University · completed · Gastric Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.